Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51

Key Points

• Qiagen has a consensus “Hold” rating from 14 brokerages, with nine holds, four buys and one strong buy. The average 12-month price target is $43.51, slightly below the reported share price of $44.15.
• Recent analyst actions were mixed: JPMorgan raised its target to $50 and assigned an “overweight” rating, while Citigroup and UBS maintained neutral ratings with targets of $45 and $47, respectively.
• Qiagen exceeded quarterly expectations, reporting earnings of $0.62 per share versus a $0.60 consensus estimate and revenue of $535.04 million versus $527.50 million expected. Institutional investors own approximately 70% of the company’s stock.

Qiagen N.V. (NYSE:QGEN - Get Free Report) has been given an average rating of "Hold" by the fourteen brokerages that are covering the company, Marketbeat reports. Nine analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $43.51.

QGEN has been the topic of a number of research analyst reports. Citigroup restated a "neutral" rating and issued a $45.00 target price (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. Weiss Ratings upgraded Qiagen from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, September 11th. JPMorgan Chase & Co. boosted their price objective on Qiagen from $45.00 to $50.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. TD Cowen reissued a "hold" rating on shares of Qiagen in a report on Wednesday, July 15th. Finally, UBS Group assumed coverage on shares of Qiagen in a research report on Wednesday, September 9th. They issued a "neutral" rating and a $47.00 price objective on the stock.

Hedge Funds Weigh In On Qiagen

A number of institutional investors have recently made changes to their positions in QGEN. Norges Bank bought a new position in shares of Qiagen during the fourth quarter valued at about $166,500,000. Deutsche Bank AG increased its holdings in shares of Qiagen by 9.7% in the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company's stock worth $355,614,000 after buying an additional 697,342 shares during the period. Amundi lifted its stake in shares of Qiagen by 12.4% in the 1st quarter. Amundi now owns 4,757,681 shares of the company's stock valued at $190,498,000 after acquiring an additional 524,959 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Qiagen in the 1st quarter valued at about $14,647,000. Finally, Troluce Capital Advisors LLC purchased a new stake in Qiagen during the 1st quarter valued at about $14,514,000. Institutional investors own 70.00% of the company's stock.

Qiagen Stock Down 0.9%

Shares of NYSE:QGEN opened at $44.15 on Friday. The firm has a fifty day moving average price of $42.79 and a two-hundred day moving average price of $39.89. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. Qiagen has a one year low of $32.53 and a one year high of $57.81. The company has a market cap of $9.10 billion, a price-to-earnings ratio of 22.62, a PEG ratio of 4.44 and a beta of 0.63.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The firm had revenue of $535.04 million for the quarter, compared to analysts' expectations of $527.50 million. During the same quarter in the prior year, the firm posted $0.60 earnings per share. The business's quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Analysts anticipate that Qiagen will post 2.43 EPS for the current fiscal year.

About Qiagen

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.